30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Interaction Drug Food
Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Pulmonary Arterial Hypertension
Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
Adverse Drug Events
Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
Healthy
Primary: Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg) — 110.97 Ratio
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Human Immunodeficiency Virus Type 1 (HIV-1) · HIV Infections
Primary: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without…
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
HIV Infections
Primary: Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15 — 2700; 3290 ng*h/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,779.08; 5,266.92 pg/mL
HIV
Primary: AUC — 94.17; 34.67; 100.44; 32.58 h*microgram/mL
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,737.00; 3,051.76 pg/mL
Drug-drug Interaction
Primary: AUC — 242; 642; 124; 371 ng/mL·h